GlassScriptPhysician profile
Thomas R Leonard
NPI 1194728949
$3,648.96
in general payments reported to CMS, 2019-2025
32 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $509 · 2021: $624 · 2022: $448 · 2023: $331 · 2024: $519 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.08 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $893.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $669.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $297.01 | 2019-2025 | |
| Lilly USA, LLC | $274.20 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.67 | 2019-2025 | Jardiance |
| Abbvie INC. | $154.18 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $129.34 | 2019-2021 | |
| Glaxosmithkline, LLC. | $113.94 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $89.51 | 2021-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Ironwood Pharmaceuticals, INC | $83.36 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $74.40 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $60.45 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $48.74 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $47.69 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $39.08 | 2024-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $31.02 | 2024-2025 | Voquezna |
| Kaleo, INC. | $28.57 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $22.99 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $22.38 | 2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $21.91 | 2022 | |
| Agepha Pharma Fz LLC | $20.45 | 2025 | Lodoco |
| Novartis Pharmaceuticals Corporation | $19.27 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2025 | Rexulti |
| Gilead Sciences, INC. | $18.04 | 2025 | |
| Dexcom, INC. | $15.38 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.54 | 2022 | |
| Currax Pharmaceuticals LLC | $13.24 | 2019 | |
| Amgen INC. | $13.15 | 2024 | Repatha, Otezla |
| Abbott Laboratories | $12.70 | 2022 | |
| Adlon Therapeutics L.P. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.